Table 1: Demographic and clinical characteristics, histological and immunologic features, and treatments used in the cohort of SLE transplanted patients.

Demographic characteristics
 Gender female32 (80%)
 Ethnicity
  Caucasians38 (95%)
  Hispanics2 (5%)
Age at SLE diagnosis (years)22.7 ± 10.5
Age at renal transplantation (years)36 ± 10.4
Time between SLE diagnosis and lupus nephritis (months)28.4 ± 65.1
Time between lupus nephritis and onset of dialysis (months)68.8 ± 72.3
Time on dialysis (months)50 ± 49.4
Time between diagnosis of lupus nephritis and transplantation (months)118 ± 69
Time of followup (months)71.4 ± 41
Histological diagnosis at onset of lupus nephritis:
 Type IV 26 (72%)
 Type III3 (8%)
 Type II2 (5%)
 Type V2 (5%)
 Type VI1 (3%)
 Interstitial nephritis1 (3%)
 Thrombotic microangiopathy1 (3%)
 Unknown4 (10%)
Number of transplantations
 First transplantation34 (68%)
 Second transplantation12 (24%)
 Third transplantation4 (8%)
Donor source
 Cadaveric donor29 (58%)
 Living donor21 (42%)
  HLA identical siblings4 (19%)
  Other genetically related13 (62%)
  Unrelated donors 4 (19%)
Immunologic features at renal transplantation
 Antinuclear antibodies50 (100%)
 Anti-dsDNA antibodies30 (60%)
 Anti-phospholipid antibodies12 (63%)
Treatments
 Cyclosporine/tacrolimus19/27
 Azathioprine/mycophenolic acid6/38
 Sirolimus3
 ATG/OKT3/Basiliximab/no induction23/1/9/17
Graft failure (%)15 (30%)

Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage). Treatments are presented as number of transplantations.
SLE: systemic lupus erythematosus; ATG: antithymocyte globulin; OKT3: orthoclone.